Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Inventory (2021 - 2025)

Ascendis Pharma A's Inventory history spans 3 years, with the latest figure at $224.8 million for Q4 2023.

  • For Q4 2023, Inventory rose 68.62% year-over-year to $224.8 million; the TTM value through Dec 2023 reached $224.8 million, up 68.62%, while the annual FY2023 figure was $226.0 million, 64.1% up from the prior year.
  • Inventory for Q4 2023 was $224.8 million at Ascendis Pharma A, up from $133.3 million in the prior quarter.
  • Across five years, Inventory topped out at $224.8 million in Q4 2023 and bottomed at $86.3 million in Q4 2021.
  • The 3-year median for Inventory is $133.3 million (2022), against an average of $148.1 million.
  • The largest annual shift saw Inventory soared 54.55% in 2022 before it skyrocketed 68.62% in 2023.
  • A 3-year view of Inventory shows it stood at $86.3 million in 2021, then skyrocketed by 54.55% to $133.3 million in 2022, then surged by 68.62% to $224.8 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Inventory are $224.8 million (Q4 2023), $133.3 million (Q4 2022), and $86.3 million (Q4 2021).